Search research articles
Contact Us
Filters
Showing results (281-290 of 509) with videos related to
Page
of 51
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 15, 2026
FIMBRIMENOP-2402 trial: evaluating fimbriectomy with delayed oophorectomy in patients with high-risk tubo-ovarian cancer
Sophie Schoenen, Audrey Mailliez, Séverine Risbourg, et al.
BMC Health Services Research
|
November 18, 2014
Transferability of health cost evaluation across locations in oncology: cluster and principal component analysis as an explorative tool
Lionel Perrier, Alessandra Buja, Giuseppe Mastrangelo, et al.
Biology
|
April 30, 2021
The Expression of Anti-Müllerian Hormone Type II Receptor (AMHRII) in Non-Gynecological Solid Tumors Offers Potential for Broad Therapeutic Intervention in Cancer
Jean-Marc Barret, André Nicolas, Anne Jarry, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 18, 2020
A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113)
Isabelle Ray-Coquard, Helen Hatcher, Emmanuelle Bompas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2021
Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study
Maud Toulmonde, Mehdi Brahmi, Antoine Giraud, et al.
Cancer Research
|
June 24, 2011
Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer
Sana Intidhar Labidi-Galy, Vanja Sisirak, Pierre Meeus, et al.
The Lancet. Oncology
|
April 13, 2016
Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial
Olivier Mir, Claire Cropet, Maud Toulmonde, et al.
Bulletin Du Cancer
|
March 29, 2023
[Endometrial stromal sarcoma: French Guidelines from the French Sarcoma Group and the Rare Malignant Gynecologic Tumors Group]
Coriolan Lebreton, Pierre Meeus, Catherine Genestie, et al.
Cancers
|
March 29, 2023
CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data
Eleni Karamouza, Rosalind M Glasspool, Caroline Kelly, et al.
Future Oncology (London, England)
|
May 5, 2025
DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients
François Cherifi, Isabelle Ray-Coquard, Maria Jesus Rubio, et al.
Page
of 51
Search research articles
Search
Showing results (281-290 of 509) with videos related to
Sort By:
Page
of 51
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 15, 2026
FIMBRIMENOP-2402 trial: evaluating fimbriectomy with delayed oophorectomy in patients with high-risk tubo-ovarian cancer
Sophie Schoenen, Audrey Mailliez, Séverine Risbourg, et al.
BMC Health Services Research
|
November 18, 2014
Transferability of health cost evaluation across locations in oncology: cluster and principal component analysis as an explorative tool
Lionel Perrier, Alessandra Buja, Giuseppe Mastrangelo, et al.
Biology
|
April 30, 2021
The Expression of Anti-Müllerian Hormone Type II Receptor (AMHRII) in Non-Gynecological Solid Tumors Offers Potential for Broad Therapeutic Intervention in Cancer
Jean-Marc Barret, André Nicolas, Anne Jarry, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 18, 2020
A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113)
Isabelle Ray-Coquard, Helen Hatcher, Emmanuelle Bompas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2021
Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study
Maud Toulmonde, Mehdi Brahmi, Antoine Giraud, et al.
Cancer Research
|
June 24, 2011
Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer
Sana Intidhar Labidi-Galy, Vanja Sisirak, Pierre Meeus, et al.
The Lancet. Oncology
|
April 13, 2016
Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial
Olivier Mir, Claire Cropet, Maud Toulmonde, et al.
Bulletin Du Cancer
|
March 29, 2023
[Endometrial stromal sarcoma: French Guidelines from the French Sarcoma Group and the Rare Malignant Gynecologic Tumors Group]
Coriolan Lebreton, Pierre Meeus, Catherine Genestie, et al.
Cancers
|
March 29, 2023
CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data
Eleni Karamouza, Rosalind M Glasspool, Caroline Kelly, et al.
Future Oncology (London, England)
|
May 5, 2025
DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients
François Cherifi, Isabelle Ray-Coquard, Maria Jesus Rubio, et al.
Page
of 51